2026 GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Join us for an in-depth exploration of one of the most impactful developments in prescription drug benefits: GLP-1 medications for type 2 diabetes and obesity management. Drawing from PSG’s 2026 Trends in Drug Benefit Design Report, this webinar provides essential insights for pharmacy and benefits professionals navigating the complex landscape of GLP-1 coverage decisions.
The rapid adoption of GLP-1 medications has created unprecedented challenges for payers as they balance clinical effectiveness with financial sustainability. Our experts will present the latest data on coverage trends, affordability concerns, and innovative cost containment strategies being implemented across the industry.
What You’ll Learn
- Shifts in payer perspectives on obesity as a lifestyle condition versus a chronic medical condition
- Payers’ GLP-1 coverage decisions and management strategies
- Updates on affordability concerns and price willing to pay for GLP-1s for obesity
- The influence of discontinuation rates on obesity GLP-1 coverage conversations
- The role of weight management vendor partnerships as part of obesity GLP-1 coverage strategies
- Payers’ preparedness for expanded GLP-1 indications and new medications entering the market
Attendees will gain actionable strategies and insights to optimize their pharmacy benefit design for these high-impact medications in 2026 and beyond.
Expert insight from our panelists:
Morgan Lee, PhD, MPH, CPH
Vice President, Research & Marketing
Scott Halperin, PharmD
Vice President, Employer Pharmacy Benefit Consulting
Tara Higgins, PharmD
Senior Clinical Consultant